Overview

Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The study objective is to assess Efficacy and safety of Reparixin treatment as compared to placebo (both on top of standard treatment) in adult patients with severe COVID-19 pneumonia.
Phase:
Phase 3
Details
Lead Sponsor:
Dompé Farmaceutici S.p.A